Cite

HARVARD Citation

    Vitale, M. et al. (2021). Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. Expert review of anticancer therapy. 21 (11), pp. 1183-1192. [Online]. 
  
Back to record